Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
about
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's diseaseHelminths for induction of remission in inflammatory bowel diseaseOptimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel diseaseTherapeutic drug monitoring in inflammatory bowel diseaseAssessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative dataOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseUse of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesOptimizing the use of thiopurines in inflammatory bowel diseaseUse of thiopurines in inflammatory bowel disease: Safety issues.Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.Impact of medical therapy on patients with Crohn's disease requiring surgical resection.Current status of thiopurine analogues in the treatment in Crohn's disease.Methotrexate: underused and ignored?A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing!Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease.Current and emerging drugs for the treatment of inflammatory bowel disease.Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel diseaseClinical predictors of thiopurine-related adverse events in Crohn's disease.A phase II study of laquinimod in Crohn's disease.Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.Thiopurines in inflammatory bowel disease revisitedPatterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn's disease in the United States.Medical management of crohn disease.Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and review.Asia-Pacific consensus statements on Crohn's disease. Part 2: Management.Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study.Oral Manifestations of Crohn's Disease: A Case Report and Review of the LiteratureRisk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome.Familial adenomatous polyposis and Crohn's disease in one patient: dilemmas and concerns.Fistulizing Crohn's Disease.Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease.
P2860
Q24197676-331D6A51-3D52-4769-9216-7CD304225120Q24234013-DD14B7F0-0C1E-4EAB-8BC5-9D2EBC741252Q24631869-642E45D3-F8CD-4521-A51C-F3D0805DC04DQ26852729-43DB3FD9-326B-4F91-B9E5-9CC6670A35A4Q26864906-9FF55570-97DF-42DD-A998-92F3CF7F0B97Q26866940-0A02F3EB-22C8-43F5-B1C7-1880C811DB9BQ26996946-8AE4F315-B2CD-4957-93BE-F24DE1A010A2Q27008246-E41E956F-4E5B-42D1-B08A-D470F3CF4EDEQ28082687-D903C743-A86B-42F6-9DA3-355B8A0A0AE1Q33621267-B1CFF0A8-2259-4AF1-8AC8-474D34F0D393Q33725615-41D5CC37-953D-4601-A3A9-99712959854CQ34137388-F25CCFC1-1864-43F5-9C8C-B8ED14531A7BQ34235370-8E9C273A-BE50-4B35-9DD4-B612148DAA3AQ34321255-35243E4F-306C-4D80-8F02-283E12C2F0EEQ34523498-7FB9BC4E-7D21-4D7E-A207-26F26D285498Q34827304-25402858-4410-4065-9E0F-A6BE31951ACBQ34883210-345D0168-0F1B-4914-BDDC-34735DC164E0Q35760894-81D65A8A-8629-451D-B70D-60C1C132205AQ35819552-91DCDC59-FC1C-4EC4-A21D-64FE8490885FQ35891861-3A075EC7-2BFF-4D88-8EE0-A964796195CDQ36175167-D76268D9-AB49-4B6A-B9F9-C479B4CA1235Q36715034-7C312338-D59C-4F59-80C9-C78825110629Q37378129-16F90A8B-3481-4AE4-8E2B-BF8CC96052F8Q38179378-6DF34231-BEAF-4065-8C01-241A988AC020Q38186168-27066AB9-A281-46E5-8556-361BBD49B7F1Q38394726-CE6654C6-5D7E-460F-BE90-7EC867FBEB36Q38422069-3496A897-6087-4254-8A4A-E58F4BE309DEQ38560433-6F36CDE9-001D-4A1A-8E24-E01ACE4C9F88Q38706667-B06DF846-0B0F-4D4F-9A48-CD26401CBC19Q41854275-42F4E7D7-771E-4F1A-A11C-46180E23A9A6Q52578355-963B040A-CC2C-45E3-8D47-324EB9049BE6Q55162386-7FF83A8F-5F78-4F34-BBCA-0E2057496208
P2860
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@ast
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@en
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@en-gb
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@nl
type
label
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@ast
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@en
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@en-gb
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@nl
prefLabel
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@ast
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@en
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@en-gb
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@nl
P2093
P1476
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
@en
P2093
Eliza Prefontaine
John K MacDonald
Lloyd R Sutherland
P356
10.1002/14651858.CD000545.PUB3
P577
2010-06-16T00:00:00Z